What is Catalyst Pharmaceutical's stock issuance proceeds?

Catalyst Pharmaceutical (CPRX) reported stock issuance proceeds of $3.3M in Q1 2026.

What is the long-term trend for Catalyst Pharmaceutical's stock issuance proceeds?

Over 3 years (2021 to 2025), Catalyst Pharmaceutical's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $4.1M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Catalyst Pharmaceutical CPRX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

PTC TherapeuticsPTCT

$6.4M-59.3%

Edgewise Therapeutics, Inc.EWTX

$12.17M+438%

Acadia PharmaceuticalsACAD

$4.23M+130%

Dyne Therapeutics, Inc.DYN

$0-100%

Scholar RockSRRK

$98M+1,852%

Amneal Pharmaceuticals, Inc.AMRX

$38K-44.9%

Other financials

Income statement

See full

Revenue$149.4M+5.6%

Gross profit$134.9M+9.2%

Operating income$73.2M+15.6%

Net income$63.7M+12.3%

EPS (diluted)$0.50+11.1%

Balance sheet

See full

Cash & equivalents$755.9M+30.2%

Total debt$2.7M-13.3%

Total equity$1.0B+27.5%

Total assets$1.1B+26.3%

Cash flow

See full

Operating cash flow$59.6M-0.8%

CapEx$27.0K—

Free cash flow$59.6M-0.8%

Valuation

See full

Market cap$3.84B+2.7%

Enterprise value$3.09B-4.1%

P/E17.4×-1.6×

P/S6.4×-0.6×

Profitability

See full

Gross margin86%-0.2pp

Operating margin44.8%+1.6pp

Net margin37.1%+0.2pp

FCF margin34.9%-15.2pp

Returns & leverage

See full

Return on equity24.5%-4.6pp

Debt / equity0×0.0×

Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Catalyst Pharmaceutical's stock issuance proceeds?: Catalyst Pharmaceutical (CPRX) reported stock issuance proceeds of $3.3M in Q1 2026.
What is the long-term trend for Catalyst Pharmaceutical's stock issuance proceeds?: Over 3 years (2021 to 2025), Catalyst Pharmaceutical's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $4.1M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.